Analyst Price Target is $0.30
▼ -43.40% Downside Potential
This price target is based on 1 analysts offering 12 month price targets for Zomedica in the last 3 months. The average price target is $0.30, with a high forecast of $0.30 and a low forecast of $0.30. The average price target represents a -43.40% upside from the last price of $0.53.
Current Consensus is
The current consensus among 1 investment analysts is to buy stock in Zomedica. This Buy consensus rating has held steady for over two years.
Zomedica Corp., a veterinary health company, focuses on the unmet needs of clinical veterinarians by developing products for companion animals. The company engages in the development and commercialization of TRUFORMA, a diagnostic biosensor platform for the detection of thyroid disorders in dogs and cats, and adrenal disorders in dogs. It has collaboration agreements with Celsee, Inc. for the development and commercialization of liquid biopsy assays and related consumables for the detection of cancer in companion animals; and Seraph Biosciences, Inc. for development and commercialization of novel pathogen detection system. The company was formerly known as Zomedica Pharmaceuticals Corp. and changed its name to Zomedica Corp. in October 2020. Zomedica Corp. was founded in 2015 and is headquartered in Ann Arbor, Michigan.